Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors

@article{Fride2005PeripheralBN,
  title={Peripheral, but not central effects of cannabidiol derivatives: Mediation by CB1 and unidentified receptors},
  author={Ester Fride and Datta E. Ponde and Aviva Breuer and Lum{\'i}r Ondřej Hanu{\vs}},
  journal={Neuropharmacology},
  year={2005},
  volume={48},
  pages={1117-1129}
}
Delta-9 tetrahydrocannabinol (Delta(9)-THC) and (-)-cannabidiol ((-)-CBD) are major constituents of the Cannabis sativa plant with different pharmacological profiles: (Delta(9)-THC activates cannabinoid CB(1) and CB(2) receptors and induces psychoactive and peripheral effects. (-)-CBD possesses no, or very weak affinity for these receptors. We tested a series of (+)- and (-)-CBD derivatives for central and peripheral effects in mice. None of the (-)-CBD derivatives were centrally active, yet… Expand
New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
TLDR
Surprisingly, it is found that hydrogenated CBD and CBD-DMH exhibit good binding to the cannabinoid receptor (CB(1), and demonstrate bioactivities different from their original compounds. Expand
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
  • S. Burstein
  • Chemistry, Medicine
  • Bioorganic & medicinal chemistry
  • 2015
TLDR
Attention will be focused on the effects of CBD in the broad area of inflammation where such benefits seem likely to be developed and the medicinal chemistry of CBD, CBD receptor binding involved in controlling Inflammation, signaling events generated by CBD, downstream events affected by CBD. Expand
Using (+)-Carvone to access novel derivatives of (+)-ent-Cannabidiol: the first asymmetric syntheses of (+)-ent-CBDP and (+)-ent-CBDV.
(-)-Cannabidiol [(-)-CBD] has recently gained prominence as a treatment for neuro-inflammation and other neurodegenerative disorders; interest is also developing in its synthetic enantiomer, (+)-CBD,Expand
Synthetic Strategies for (-)-Cannabidiol and Its Structural Analogs.
TLDR
This review concisely summarizes the historic and recent milestones in the synthetic strategies for (-)-CBD and its analogs and generates novel (--CBD analogs that exhibit advanced biological activities. Expand
Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease.
TLDR
11 general types of natural cannabinoids from Cannabis sativa as well as 50 (-)-CBD analogues with therapeutic potential were described and CBD prevents the glycogen synthase kinase 3β (GSK-3β) hyperphosphorylation caused by Aβ and may be developed as a new therapeutic candidate for Alzheimer's disease. Expand
The endocannabinoid-CB receptor system: a new player in the brain-gut-adipose field
TLDR
TheECBR system is a major mediator between the brain and the alimentary system, and possibly, the adipose tissue, and the role of the ECBR system in adult regulation of food processing is a remnant of its critical role for the initiation of feeding in the newborn. Expand
Targeting cannabinoid agonists for inflammatory and neuropathic pain
TLDR
A large body of preclinical data supports the hypothesis that either CB2-selective agonists or CB1 agonists acting at peripheral sites, or with limited CNS exposure, will inhibit pain and neuroinflammation without side effects within the CNS. Expand
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
TLDR
The main biological effects of CBD, and its synthetic derivatives, are reviewed, focusing on the cellular, antioxidant, and anti-inflammatory properties of CBD. Expand
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
TLDR
Current knowledge on the pharmacokinetics and metabolic fate of CBD in humans is summarized, studies on the biological activity of CBD metabolites either in vitro or in vivo are reviewed, and relevant drug–drug interactions are discussed. Expand
Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?
TLDR
The hemp plant is looked at as a possible source of new functional food ingredients and nutraceuticals that might be eventually useful to treat or even prevent gastrointestinal conditions and the available data showing that non-psychoactive phytocannabinoids, particularly cannabidiol, may be useful to treatment different disorders and diseases of the gastrointestinal tract are revised. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 55 REFERENCES
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
TLDR
It is concluded that centrally inactive (+)-cannabidiol analogues should be further developed as antidiarrheal, antiinflammatory and analgesic drugs for gastrointestinal and other peripheral conditions. Expand
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens.
TLDR
It is concluded that cannabidiol antagonizes R-(+)-WIN55212 and CP55940 by acting at prejunctional sites that are unlikely to be cannabinoid CB(1) or CB(2) receptors. Expand
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
  • L. Hanuš, A. Breuer, +7 authors E. Fride
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity, demonstrating the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain. Expand
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals.
TLDR
The results suggest that these compounds exert their inhibitory effects through cannabinoid CB1 receptors in the myenteric plexus preparation, but mainly through CB2-like cannabinoid receptors inThe vas deferens. Expand
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
TLDR
Results suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues, and (−)‐5′‐DMH‐CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent. Expand
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
TLDR
The structural diversity and wide-ranging potencies of the analogs described herein provide the opportunity to develop a pharmacophore for the cannabinoids using molecular modeling techniques. Expand
[Endocannabinoids in the central nervous system].
TLDR
Endocannabinoids transiently silence synapses by decreasing neurotransmitter release, play major parts in various forms of synaptic plasticity because of their ability to behave as retrograde messengers and activate non-cannabinoid receptors (such as vanilloid receptor type-1), illustrating the complexity of the endocannabinoid system. Expand
The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
TLDR
Investigation of the effects of cannabinoid receptor agonists and exogenous activation of cannabinoid CB(1) receptors suggests intestinal motility and defaecation could be tonically inhibited by the endogenous cannabinoids. Expand
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
  • Z. Járai, J. Wagner, +10 authors G. Kunos
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
It is suggested that Abn-cbd and cannabidiol are a selective agonist and antagonist, respectively, of an as-yet-unidentified endothelial receptor for anandamide, activation of which elicits NO-independent mesenteric vasodilation, possibly by means of the release of an endothelium-derived hyperpolarizing factor (EDHF). Expand
Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
TLDR
The results indicate that anandamide modulates intestinal motility in mice by activating cannabinoid CB1 receptors and suggest that ananandamide transport, which was previously shown to participate in terminating neural and vascular responses to an andamide, does not contribute toAnandamide inactivation in intestinal tissue. Expand
...
1
2
3
4
5
...